CoChat

EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial

Open access
Mitchell, Paul, Holz, Frank G., Hykin, Philip, Midena, Edoardo, Souied, Eric, Allmeier, Helmut, Lambrou, George, Schmelter, Thomas, Wolf, Sebastian, on behalf of the ARIES study investigators · 2021 · Retina

The DOI matches its Crossref record; 20 of the 23 references it cites were found in a registry or an index.

Abstract

Background/Purpose: Treating neovascular age-related macular degeneration with intravitreal aflibercept treat-and-extend (T&E) can reduce treatment burden. ARIES assessed whether intravitreal aflibercept early-start T&E was noninferior to late-start T&E. Methods: A randomized, open-label, Phase 3b/4 study that included treatment-naïve patients aged ≥50 years with the best-corrected visual acuity 73–25 Early Treatment Diabetic Retinopathy Study letters and active choroidal neovascularization secondary to AMD. Patients received 2 mg intravitreal aflibercept at Week (W) 0, W4, W8, and W16. At W16, patients were randomized 1:1 to early-start (2W interval adjustments) or late-start T&E (8W intervals until W48 then 2W interval adjustments). Primary endpoint: the best-corrected visual acuity change from randomization to W104. Results: Two-hundred seventy-one patients were randomized. The mean (SD) best-corrected visual acuity at baseline was 60.2 (12.1; early-T&E) and 61.3 (10.8; late-T&E) letters. The mean (SD) best-corrected visual acuity change (W16–104) was −2.1 (11.4) versus −0.4 (8.4) letters (early-T&E vs. late-T&E; least-squares mean difference: −2.0; 95% confidence interval: −4.75 to 0.71; P = 0.0162 for noninferior); +4.3 (13.4) versus +7.9 (11.9) letters (W0–104). The mean (SD) number of injections was 12.0 (2.3) versus 13.0 (1.8). From baseline to W104, 93.4% and 96.2% maintained best-corrected visual acuity; the mean (SD) central retinal thickness change was −161.6 (135.6) µ m and −158.6 (125.1) µ m. The last injection interval (W104) was ≥12W for 47.2% and 51.9% of patients. Conclusion: Outcomes were similar between patients with neovascular age-related macular degeneration treated with an intravitreal aflibercept early-T&E or late-T&E regimen after initial dosing, with one injection difference over 2 years. Trial Registration: ClinicalTrials.gov Identifier: NCT02581891 https://clinicaltrials.gov/ct2/show/NCT02581891. Supplemental Digital Contents (files 1 http://links.lww.com/IAE/B419).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/iae.0000000000003128

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. ARIES study design. *Patients were stratified based on visual outcomes from baseline to Week 16 (<8 letters or ≥8 letters gain in the BCVA). †If no IRF and no SRF at Week 16, treatment could be extended from 8 to 12 weeks. ‡Injection interval could be extended to a maximum of 16 weeks. 2q8, every 8 weeks; IRF, intraretinal fluid; R, randomization; SRF, subretinal fluid.
Fig. 1. ARIES study design. *Patients were stratified based on visual outcomes from baseline to Week 16 (<8 letters or ≥8 letters gain in the BCVA). †If no IRF and no SRF at Week 16, treatment could be extended from 8 to 12 weeks. ‡Injection interval could be extended to a maximum of 16 weeks. 2q8, every 8 weeks; IRF, intraretinal fluid; R, randomization; SRF, subretinal fluid.CC BY-NC-ND · PubMed Central
Fig. 2. Patient disposition. *One patient discontinued during the follow-up period after completion of treatment.
Fig. 2. Patient disposition. *One patient discontinued during the follow-up period after completion of treatment.CC BY-NC-ND · PubMed Central
Fig. 3. A. The mean BCVA change (Week 16 to Week 104). B. Absolute BCVA (baseline to Week 104; PPS). Error bars indicate standard error of the mean. Analyses were conducted as a last observation carried forward from the PPS. *Adjusted treatment difference (least squares means). †CI excludes −5 (prespecified noninferiority margin).
Fig. 3. A. The mean BCVA change (Week 16 to Week 104). B. Absolute BCVA (baseline to Week 104; PPS). Error bars indicate standard error of the mean. Analyses were conducted as a last observation carried forward from the PPS. *Adjusted treatment difference (least squares means). †CI excludes −5 (prespecified noninferiority margin).CC BY-NC-ND · PubMed Central
Fig. 4. Duration of last treatment interval up to Week 104 (PPS). Analyses were conducted as a LOCF from the PPS. Intervals greater than 16 weeks were considered minor deviations and were included in the PPS. LOCF, last observation carried forward.
Fig. 4. Duration of last treatment interval up to Week 104 (PPS). Analyses were conducted as a LOCF from the PPS. Intervals greater than 16 weeks were considered minor deviations and were included in the PPS. LOCF, last observation carried forward.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 1

  1. Do, 2017, Pharmacokinetics of free aflibercept in patients with neovascular age related macular degeneration, Invest Ophthalmol Vis Sci, 58, 406

Cited by

See all 106

Metadata

Authors
Mitchell, P., Holz, F. G., Hykin, P., Midena, E., Souied, E., Allmeier, H., Lambrou, G., Schmelter, T., Wolf, S., & on behalf of the ARIES study investigators
Affiliations
  • The University of Sydney (AU)
  • University of Bonn (DE)
  • Moorfields Eye Hospital (GB)
  • University of Padua (IT)
  • Hôpital Intercommunal de Créteil (FR)
  • Bayer (Switzerland) (CH)
  • Bayer (Germany) (DE)
  • Department for Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland.
Corresponding author
  • Mitchell, Paul
  • Allmeier, Helmut
  • Lambrou, George
Venue
Retina
Published
2021-09
Volume
41
Issue
9
Pages
1911-1920
ISSN
0275-004X (ISSN-L)
OpenAlex
W3146812839
Cited by
101
References
23
Citations by year
2026: 13 · 2025: 24 · 2024: 21 · 2023: 18 · 2022: 20 · 2021: 5
FWCI
14.36
Type
journal article
Language
en
Open access
Locations
  • Retina (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion)
  • Padua Research Archive (University of Padova) (submittedVersion, cc-by-nc-nd)
Funders
  • Bayer HealthCare
  • Allergan
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
neovascular age-related macular degeneration, aflibercept, intravitreal injection, treat-and-extend regimen, choroidal neovascularization, visual acuity, non-inferiority, treatment burden, anti-VEGF therapy, central retinal thickness, treatment-naive patients, treatment efficacy and safety, endophthalmitis
MeSH terms
Ranibizumab, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Macula Lutea, Male, Middle Aged, Recombinant Fusion Proteins, Time Factors, Visual Acuity, Treatment Outcome, Angiogenesis Inhibitors, Receptors, Vascular Endothelial Growth Factor, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1097/iae.0000000000003128
The paper
Mitchell, P., Holz, F. G., Hykin, P., Midena, E., Souied, E., Allmeier, H., Lambrou, G., Schmelter, T., Wolf, S., & on behalf of the ARIES study investigators. (2021). EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical Trial. Retina. https://doi.org/10.1097/iae.0000000000003128

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.